The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCINE.L Regulatory News (CINE)

  • There is currently no data for CINE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Rump Placing

20 Feb 2018 14:39

RNS Number : 4271F
Cineworld Group plc
20 February 2018
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, HONG KONG OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND NOT A PROSPECTUS AND THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM PART OF, AND SHOULD NOT BE CONSTRUED AS, ANY OFFER, INVITATION OR RECOMMENDATION TO PURCHASE, SELL OR SUBSCRIBE FOR ANY SECURITIES IN ANY JURISDICTION AND NEITHER THE ISSUE OF THE INFORMATION NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF OR BE RELIED UPON IN CONNECTION WITH, OR ACT AS AN INDUCEMENT TO ENTER INTO, ANY INVESTMENT ACTIVITY. ANY DECISION TO PURCHASE, SUBSCRIBE FOR, OTHERWISE ACQUIRE, SELL OR OTHERWISE DISPOSE OF ANY SECURITIES MUST BE MADE ONLY ON THE BASIS OF THE INFORMATION CONTAINED IN AND INCORPORATED BY REFERENCE INTO THE PROSPECTUS

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT

FOR IMMEDIATE RELEASE

20 February 2018

CINEWORLD GROUP PLC

RESULTS OF RUMP PLACING

Following the announcement earlier today regarding valid acceptances under the fully underwritten Rights Issue announced by Cineworld Group plc ("Cineworld" or the "Company") on 17 January 2018, the Company confirms that Barclays Bank PLC, HSBC Bank plc and Investec Bank plc have procured subscribers for all of the 40,383,167 New Ordinary Shares for which valid acceptances were not received, representing approximately 3.69 per cent. of the total number of New Ordinary Shares, at a price of 238 pence per New Ordinary Share.

The net proceeds from the placing of such New Ordinary Shares (after the deduction of the Rights Issue Price of 157 pence per New Ordinary Share and the expenses of procuring subscribers including any applicable brokerage and commissions and amounts in respect of VAT which are not recoverable, if any) will be paid (without interest) to those persons whose rights have lapsed in accordance with the terms of the Rights Issue, pro rata to their lapsed provisional allotments, save that individual amounts of less than £5.00 will not be paid to such persons but will be paid to the Company.

Following the allotment of the New Ordinary Shares to reflect the shares for which Barclays Bank PLC, HSBC Bank plc and Investec Bank plc have procured subscribers, the Company's issued share capital will consist of 1,369,631,475 ordinary shares of one pence each. The Company holds no ordinary shares in treasury. Therefore, as at 20 February 2018, the total number of voting rights in the Company is 1,369,631,475. This figure may be used by Shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change in their interest in, the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

As announced earlier today, the Company currently expects Completion to occur after market hours (London time) on 28 February 2018 and that Re-admission will occur at 8.00am on 1 March 2018.

Capitalised terms used in this announcement have the meanings given to them in the combined prospectus and class 1 circular dated 17 January 2018 (the "Prospectus"), which is available on the Company's website (www.cineworldplc.com) and may be inspected at the registered office of the Company at 8th Floor, Vantage London, Great West Road, Brentford TW8 9AG during normal business hours on any Business Day up to and including the date of Re-admission.

For further details please contact:

Cineworld Group plc

+44 (0)20 8987 5000

Israel Greidinger

 

Nisan Cohen

 

 

 

 

 

 

 

Barclays (Joint Financial Adviser, Joint Underwriter, Joint Global Coordinator and Joint Corporate Broker to Cineworld)

+44 (0)20 7623 2323

Makram Azar

 

Daniel Ross

 

Mark Astaire

 

James Colburn

 

 

 

 

 

HSBC (Joint Financial Adviser, Joint Underwriter and Joint Global Coordinator to Cineworld)

+44 (0)20 7991 8888

Philip Noblet

 

Noam Kleinfeld

 

James Thomlinson

 

Mark Dickenson

 

Sam Barnett

 

 

 

Investec Bank plc (Sponsor, Joint Underwriter, Joint Bookrunner and Joint Corporate Broker to Cineworld)

+44 (0)20 7597 4000

 

 

Chris Sim

 

George Price

 

Jonathan Wynn

 

Robert Baker

 

 

 

 

 

Powerscourt (Public Relations Adviser to Cineworld)

+44 (0)20 7250 1446

 

 

Nick Dibden

 

Rob Greening

 

Lisa Kavanagh

 

IMPORTANT NOTICE

The contents of this announcement have been prepared by and are the sole responsibility of Cineworld.

This announcement is not a prospectus but an advertisement and investors should not acquire any securities referred to in this announcement except on the basis of the information contained in the Prospectus. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed by any person for any purpose on the information contained in this announcement or its accuracy, fairness or completeness.

Neither the content of Cineworld's website nor any website accessible by hyperlinks on Cineworld's website is incorporated in, or forms part of, this announcement.

This announcement is not for publication or distribution, directly or indirectly, in or into the United States. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy, securities to any person in the United States, Australia, Canada, Japan, Hong Kong or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States unless registered under the US Securities Act of 1933, as amended (the "Securities Act") or offered in a transaction exempt from, or not subject to, the registration requirements of the Securities Act. The offer and sale of securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada, Japan or Hong Kong. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada, Japan or Hong Kong or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Japan or Hong Kong. There will be no public offer of the securities in the United States, Australia, Canada, Japan or Hong Kong.

This announcement does not constitute a recommendation concerning participation in the Rights Issue. The price and value of securities can go down as well as up. Past performance is not a guide to future performance. The contents of this announcement are not to be construed as legal, business, financial or tax advice. Each shareholder or prospective investor should consult his, her or its own legal adviser, business adviser, financial adviser or tax adviser for legal, financial, business or tax advice.

Each of Barclays Bank PLC, acting through its Investment Bank ("Barclays"), HSBC Bank plc ("HSBC") and Investec Bank plc ("Investec" and together with Barclays and HSBC, the "Underwriters") is authorised by the Prudential Regulation Authority and regulated in the United Kingdom by the Financial Conduct Authority and the Prudential Regulation Authority. Each of the Underwriters is acting exclusively for Cineworld and no one else in connection with the Transaction or any other matter referred to in this announcement and will not be responsible to anyone other than Cineworld for providing the protections afforded to their respective clients nor for providing advice in relation to the Transaction or any other matter referred to in this announcement. Neither the Underwriters nor any of their respective subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of the Underwriters in connection with this announcement, any statements contained herein or otherwise.

Information to Distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Nil Paid Rights, the Fully Paid Rights and the New Ordinary Shares have been subject to a product approval process, which has determined that they each are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares may decline and investors could lose all or part of their investment; the Nil Paid Rights, the Fully Paid Rights and the New Ordinary Shares offer no guaranteed income and no capital protection; and an investment in the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the offer. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Underwriters will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares and determining appropriate distribution channels.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROIFKKDNQBKDPBB
Date   Source Headline
31st Jul 20233:10 pmRNSEntry of Cineworld Group plc into Administration
28th Jul 20237:30 amRNSSuspension - Cineworld Group PLC
28th Jul 20237:00 amRNSSuspension of Cineworld’s Listing
29th Jun 20237:00 amRNSConfirmation of Plan of Reorganisation
26th Jun 20239:50 amRNSDirector Declaration
26th Jun 20237:00 amRNSChapter 11 Update
25th May 20237:00 amRNSChapter 11 update
9th May 202312:24 pmRNSBLOCK LISTING SIX MONTHLY RETURN
20th Apr 202311:15 amRNSGeneral Meeting
18th Apr 20237:00 amRNSChapter 11 Update
11th Apr 20237:00 amRNSChapter 11 Update
3rd Apr 20237:00 amRNSChapter 11 Update
23rd Mar 20232:58 pmRNSNotice of General Meeting
9th Mar 20234:35 pmRNSPrice Monitoring Extension
8th Mar 20234:35 pmRNSPrice Monitoring Extension
2nd Mar 20234:35 pmRNSPrice Monitoring Extension
24th Feb 20234:35 pmRNSPrice Monitoring Extension
24th Feb 20237:00 amRNSUpdate on Chapter 11 cases
1st Feb 20234:35 pmRNSPrice Monitoring Extension
27th Jan 202312:49 pmRNSCommittee Changes
3rd Jan 20237:00 amRNSUpdate on Chapter 11 cases and marketing process
14th Dec 20221:00 pmRNSDirectorate Change
12th Dec 20225:32 pmRNSDirector Update
8th Dec 20224:35 pmRNSPrice Monitoring Extension
9th Nov 20229:18 amRNSBLOCK LISTING SIX MONTHLY RETURN
1st Nov 20224:40 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
28th Oct 20224:41 pmRNSSecond Price Monitoring Extn
28th Oct 20224:35 pmRNSPrice Monitoring Extension
14th Oct 20224:41 pmRNSSecond Price Monitoring Extn
14th Oct 20224:36 pmRNSPrice Monitoring Extension
7th Oct 20224:41 pmRNSSecond Price Monitoring Extn
7th Oct 20224:36 pmRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSInterim Results for the period ended 30 June 2022
29th Sep 20224:40 pmRNSSecond Price Monitoring Extn
29th Sep 20224:35 pmRNSPrice Monitoring Extension
22nd Sep 20224:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:36 pmRNSPrice Monitoring Extension
20th Sep 20222:17 pmRNSUpdate Regarding Interim Results
20th Sep 20227:00 amRNSHolding(s) in Company
15th Sep 20229:33 amRNSHolding(s) in Company
15th Sep 20227:15 amRNSDirector Declaration
12th Sep 20224:41 pmRNSSecond Price Monitoring Extn
12th Sep 20224:36 pmRNSPrice Monitoring Extension
9th Sep 20224:41 pmRNSSecond Price Monitoring Extn
9th Sep 20224:36 pmRNSPrice Monitoring Extension
9th Sep 20228:21 amRNSReceives Court Approval for “First Day” Relief
8th Sep 20225:30 pmRNSCineworld Group
7th Sep 20223:45 pmRNSCommencement of Chapter 11 Cases
1st Sep 20229:54 amRNSStandard form for notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.